Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

LBPS

4D Pharma (LBPS)

4D Pharma PLC
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:LBPS
日付受信時刻ニュースソース見出しコード企業名
2023/01/0402 : 10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/11/1603 : 54Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/10/0723 : 59Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/10/0104 : 04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/08/2505 : 44Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/07/2000 : 49Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LBPS4D Pharma PLC
2022/07/0603 : 07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/06/3003 : 26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/06/2902 : 50Business Wire4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqNASDAQ:LBPS4D Pharma PLC
2022/06/2721 : 15TipRanksWhat Made Chardan Capital Downgrade 4d Pharma’s Stock?NASDAQ:LBPS4D Pharma PLC
2022/06/2506 : 20Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/06/2504 : 32TipRanksLadenburg Thalmann & Co. Downgrades 4d Pharma (LBPS) to HoldNASDAQ:LBPS4D Pharma PLC
2022/06/2503 : 41Business WireUpdate on Suspension of TradingNASDAQ:LBPS4D Pharma PLC
2022/06/2422 : 20Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/06/0204 : 32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/05/2706 : 30Business Wire4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LBPS4D Pharma PLC
2022/05/2005 : 30Business Wire4D pharma to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:LBPS4D Pharma PLC
2022/05/1720 : 00Business Wire4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceNASDAQ:LBPS4D Pharma PLC
2022/04/2919 : 34Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
2022/04/0106 : 27Business Wire4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022NASDAQ:LBPS4D Pharma PLC
2022/03/3119 : 25Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
2022/03/2906 : 29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:LBPS4D Pharma PLC
2022/03/2320 : 46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
2022/03/2320 : 00Business Wire4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaNASDAQ:LBPS4D Pharma PLC
2022/03/0307 : 26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LBPS4D Pharma PLC
2022/03/0106 : 34Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:LBPS4D Pharma PLC
2022/02/2321 : 00Business Wire4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitNASDAQ:LBPS4D Pharma PLC
2022/02/2221 : 00Business Wire4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseNASDAQ:LBPS4D Pharma PLC
2022/02/1907 : 03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
2022/02/1907 : 03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:LBPS